- Home
- Blog
- News
- Basics
- Sources
- Agencies, Regulatory & Organisations
- CERSI Excipients Browser
- Excipient Report
- Excipient DMF List
- EXCiPACT Certified Companies
- Excipient Documentation
- Excipient EINECS Numbers
- Excipient E-Numbers
- FDA Inactive Ingredient List
- FDA GRAS Substances (SCOGS) Database
- IPEC Americas
- USP - U.S. Pharmacopeia
- Definitions
- Whitepapers / Publications
- Supplier
- Services
- Media
- Events
- 1st pharmaexcipients Poster Award
- Event Calendar
- Events featured by pharma-excipients
- 4th Annual Formulation & Drug Delivery Congress
- DDF Summit
- ExcipientFest Americas
- ExcipientFest Asia
- Global CompliancePanel
- International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems
- Formulation & Drug Delivery USA Congress
- Laboratory Medicine 2018
- Making Pharmaceuticals Europe
- Making Pharmaceuticals Exhibition
- Pharma Integrates
- PharmaExcipients China @CPhI China
- TTC Technology Training Center
- Jobs
- Online Sourcing
- Contact
09. February 2017
Abstract: Background: Colorectal carcinoma is the fourth most common internal malignancy; it is second only to carcinoma of the lung as a cause of carcinoma death. 6-Mercaptopurine (6-MP) is a drug of choice in the treatment of Crohn's disease, ulcerative colitis and colorectal cancer. The drug shows irritation on gastric exposure. It has poor bioavailability with half life less than 2 h. Targeted delivery of 6-MP will provide an effective and safe therapy for colon diseases. Objective:...
27. January 2016
12. January 2016
23. December 2015
10. November 2015
To ensure safe oral administration, pediatric patients require an appropriate dosage form to be swallowed without relevant difficulties. Ex tempore hydrated powders, forming viscous pulp “on a spoon”, have recently gained much interest as pediatric formulations. The aim of this study was to evaluate the viscosity-increasing substances and disintegrants, alone or in mixtures, as excipients suitable for preparing such formulations, with candesartan and valsartan chosen as model active...